| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 966 | 2018 |
| Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes J Violet, P Jackson, J Ferdinandus, S Sandhu, T Akhurst, A Iravani, ... Journal of Nuclear Medicine 60 (4), 517-523, 2019 | 348 | 2019 |
| Impact of socioeconomic status on municipal solid waste generation rate D Khan, A Kumar, SR Samadder Waste management 49, 15-25, 2016 | 272 | 2016 |
| Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration … J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ... Journal of Nuclear Medicine 61 (6), 857-865, 2020 | 244 | 2020 |
| Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu … SP Thang, J Violet, S Sandhu, A Iravani, T Akhurst, G Kong, AR Kumar, ... European urology oncology 2 (6), 670-676, 2019 | 155 | 2019 |
| Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617 J Ferdinandus, J Violet, S Sandhu, RJ Hicks, AS Ravi Kumar, A Iravani, ... European journal of nuclear medicine and molecular imaging 47, 2322-2327, 2020 | 120 | 2020 |
| Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol A Iravani, B Solomon, DA Pattison, P Jackson, A Ravi Kumar, G Kong, ... Thyroid 29 (11), 1634-1645, 2019 | 88 | 2019 |
| The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT JC Lee, GF Hartnett, BGM Hughes, ASR Kumar Nuclear Medicine Communications 30 (5), 333-337, 2009 | 59 | 2009 |
| Optical differentiation between malignant and benign lymphadenopathy by grey scale texture analysis of endobronchial ultrasound convex probe images P Nguyen, F Bashirzadeh, J Hundloe, O Salvado, N Dowson, R Ware, ... Chest 141 (3), 709-715, 2012 | 45 | 2012 |
| Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine … I Goncalves, K Burbury, M Michael, A Iravani, AS Ravi Kumar, T Akhurst, ... European journal of nuclear medicine and molecular imaging 46, 1902-1910, 2019 | 44 | 2019 |
| Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma OK Hasan, ASR Kumar, G Kong, K Oleinikov, S Ben-Haim, ... Journal of Nuclear Medicine 61 (9), 1326-1330, 2020 | 26 | 2020 |
| The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma G Kong, T Schenberg, CJ Yates, A Trainer, N Sachithanandan, A Iravani, ... The Journal of Clinical Endocrinology & Metabolism 104 (11), 5091-5099, 2019 | 25 | 2019 |
| Radiation dosimetry in 177Lu-PSMA-617 therapy P Jackson, M Hofman, L McIntosh, JP Buteau, AR Kumar Seminars in Nuclear Medicine 52 (2), 243-254, 2022 | 24 | 2022 |
| PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). S Sandhu, AM Joshua, L Emmett, LA Spain, L Horvath, M Crumbaker, ... Journal of Clinical Oncology 40 (16_suppl), 5017-5017, 2022 | 23 | 2022 |
| Grey scale texture analysis of endobronchial ultrasound mini probe images for prediction of benign or malignant aetiology P Nguyen, F Bashirzadeh, J Hundloe, O Salvado, N Dowson, R Ware, ... Respirology 20 (6), 960-966, 2015 | 21 | 2015 |
| Comparison of objective criteria and expert visual interpretation to classify benign and malignant hilar and mediastinal nodes on 18‐F FDG PET/CT P Nguyen, M Bhatt, F Bashirzadeh, J Hundloe, R Ware, D Fielding, ... Respirology 20 (1), 129-137, 2015 | 21 | 2015 |
| Variable F-18 fluorodeoxyglucose avidity of metastatic recurrent adult granulosa cell tumor YT Huang, JC Lee, ASR Kumar Clinical nuclear medicine 34 (10), 710-712, 2009 | 21 | 2009 |
| alpha-Tocopherol enhances tumour growth inhibition by cis-dichlorodiammine platinum (II) S Sarna, A Kumar, RK Bhola Brazilian Journal of Medical and Biological Research 33, 929-936, 2000 | 19 | 2000 |
| Preoperative positron emission tomography for node-positive head and neck cutaneous squamous cell carcinoma N Hirshoren, E Olayos, A Herschtal, AS Ravi Kumar, DE Gyorki Otolaryngology–Head and Neck Surgery 158 (1), 122-126, 2018 | 18 | 2018 |
| 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC) SK Sandhu, AM Joshua, L Emmett, L Spain, LG Horvath, M Crumbaker, ... Annals of Oncology 32, S626-S627, 2021 | 17 | 2021 |
